|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2000-8-23
|
|
pubmed:abstractText |
A recent study has shown that losartan, an AT-1-receptor antagonist, interacts with thromboxane A2 (TxA2)/prostaglandin H2 (PGH2) receptors in human platelets. The aim of this study was to analyze the ability of different angiotensin II (Ang II) AT-1-receptor antagonists to inhibit TxA2-dependent human platelet activation. Platelets were obtained from healthy volunteers. Platelets were stimulated with the TxA2 analogue, U46619 (10(-6) M). U46619-stimulated platelet activation was significantly reduced by both losartan and irbesartan in a dose-dependent manner. Only maximal doses of valsartan (5 x 10(-6) M) and the main metabolite of losartan, EXP3174 (5 x 10(-6) M), reduced U46619-induced platelet activation. Whereas the active form of candesartan cilexetil (candesartan, CV-11974) failed to modify platelet activation involved by TxA2, telmisartan showed a higher effect than valsartan and EXP3174 but lower than either losartan and irbesartan. Losartan or irbesartan reduced the binding of [3H]-U46619 to platelets, an effect that was observed with lower ability with the other AT-1 antagonists. Although platelets expressed AT-1-type receptors, exogenous Ang II did not modify platelet activation. This effect was not modified by blocking the AT-2 receptor with PD123319. These results suggest that some AT-1-receptor antagonists reduce TxA2-dependent activation independent of Ang II involvement.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/15-Hydroxy-11 alpha,9...,
http://linkedlifedata.com/resource/pubmed/chemical/Adenosine Diphosphate,
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin II,
http://linkedlifedata.com/resource/pubmed/chemical/Angiotensin Receptor Antagonists,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Benzimidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Benzoates,
http://linkedlifedata.com/resource/pubmed/chemical/Biphenyl Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/EXP3174,
http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Losartan,
http://linkedlifedata.com/resource/pubmed/chemical/PD 123319,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Angiotensin, Type 1,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Angiotensin, Type 2,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Angiotensin,
http://linkedlifedata.com/resource/pubmed/chemical/Tetrazoles,
http://linkedlifedata.com/resource/pubmed/chemical/Thromboxane A2,
http://linkedlifedata.com/resource/pubmed/chemical/Valine,
http://linkedlifedata.com/resource/pubmed/chemical/candesartan,
http://linkedlifedata.com/resource/pubmed/chemical/irbesartan,
http://linkedlifedata.com/resource/pubmed/chemical/telmisartan,
http://linkedlifedata.com/resource/pubmed/chemical/valsartan
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0160-2446
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
35
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
906-13
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:10836725-15-Hydroxy-11 alpha,9...,
pubmed-meshheading:10836725-Adenosine Diphosphate,
pubmed-meshheading:10836725-Adult,
pubmed-meshheading:10836725-Angiotensin II,
pubmed-meshheading:10836725-Angiotensin Receptor Antagonists,
pubmed-meshheading:10836725-Antibodies, Monoclonal,
pubmed-meshheading:10836725-Benzimidazoles,
pubmed-meshheading:10836725-Benzoates,
pubmed-meshheading:10836725-Binding, Competitive,
pubmed-meshheading:10836725-Biphenyl Compounds,
pubmed-meshheading:10836725-Blood Platelets,
pubmed-meshheading:10836725-Dose-Response Relationship, Drug,
pubmed-meshheading:10836725-Humans,
pubmed-meshheading:10836725-Imidazoles,
pubmed-meshheading:10836725-Losartan,
pubmed-meshheading:10836725-Platelet Activation,
pubmed-meshheading:10836725-Pyridines,
pubmed-meshheading:10836725-Radioligand Assay,
pubmed-meshheading:10836725-Receptor, Angiotensin, Type 1,
pubmed-meshheading:10836725-Receptor, Angiotensin, Type 2,
pubmed-meshheading:10836725-Receptors, Angiotensin,
pubmed-meshheading:10836725-Tetrazoles,
pubmed-meshheading:10836725-Thromboxane A2,
pubmed-meshheading:10836725-Time Factors,
pubmed-meshheading:10836725-Valine
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Comparative effects of angiotensin II AT-1-type receptor antagonists in vitro on human platelet activation.
|
|
pubmed:affiliation |
Cardiovascular Research and Hypertension Laboratory, Fundación Jiménez Díaz, Madrid, Spain.
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Research Support, Non-U.S. Gov't
|
